Dronedarone | SR 33589 | Autophagy | AChR | AmBeed-信号通路专用抑制剂

首页 / 抑制剂/激动剂 / / / Dronedarone

决奈达隆 /Dronedarone {[allProObj[0].p_purity_real_show]}

货号：A404830 同义名： SR 33589

Dronedarone是胺碘酮的衍生物，是一种用于研究心房颤动（AF）的 III 类抗心律失常试剂。它是多种离子电流（包括钾电流、钠电流和 L 型钙电流）的有效阻滞剂，并通过非竞争性结合肾上腺素能受体发挥抗肾上腺素能作用。此外，Dronedarone 是 CYP3A4 的底物和中度抑制剂，广泛用于心律失常机制和药理研究。

Dronedarone 化学结构
CAS号：141626-36-0

Dronedarone 3D分子结构
CAS号：141626-36-0

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Dronedarone 纯度/质量文件产品仅供科研

货号：A404830 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • ACS Appl. Nano Mater., 2025. Ambeed. [ A188026 ]; • Eur. J. Clin. Microbiol. Infect. Dis., 2025. Ambeed. [ A151161 ]; • JJC, 2025, 20(Special Issue)): 27-39. Ambeed. [ A713856 ]; • bioRxiv, 2025. Ambeed. [ A538667 , A714873 , A126729 , A126049 , A446054 ]; • Nature Communications, 2025, 16, 1871. Ambeed. [ A508148 ]; 更多 >

自噬亚型比较
AChR 亚型比较

产品名称	Autophagy ↓ ↑	其他靶点	纯度
SBI-0206965	+++ ULK2, IC50: 711 nM ULK1, IC50: 108 nM		95%
Hydroxychloroquine sulfate	✔		99%
Valproic acid sodium	✔	HDAC	97%
PFK-015	++ PFKFB3, IC50: 207 nM		99%+
MRT68921 hydrochloride	++++ ULK2, IC50: 1.1 nM ULK1, IC50: 2.9 nM		99%+
ROC-325	✔		99%+
Autophinib	+++ Autophagy, IC50: 40 nM		99%
Lys05	✔		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	AChE ↓ ↑	AChR ↓ ↑	mAChR ↓ ↑	nAChR ↓ ↑	其他靶点	纯度
Donepezil	+++ bAChE, IC50: 8.12 nM hAChE, IC50: 11.6 nM					98%
Loganin	++ AChE, IC50: 3.95 μM					99%+
topride HCl	++ AChE, IC50: 2.04 μM					98%
Dehydroevodiamine HCl	✔					99%+
Jatrorrhizine	++ AChE, IC50: 872 nM					99%+
Palmatine	++ AChE, IC50: 0.51 μM					98%
(-)-Huperzine A	++++ AChE (G4 form), Ki: 7 nM					98%
Galanthamine HBr	++ AChE, IC50: 0.35 μM					98%
Trospium chloride		✔				99%
Tiotropium Bromide Monohydrate		✔				97%
Gallamine Triethiodide		+ AChR, IC50: 68.0 μM				98%
Hexamethonium Bromide		✔				99%
Pancuronium dibromide		✔				98%
Neostigmine bromide		✔				98%
Orphenadrine citrate		✔				98%
Oxybutynin		✔				98%
Irsogladine		✔			PDE	99%
Pyridostigmine bromide		✔				99+%
Rivastigmine		+ AChR, IC50: 5.5 μM				98%
Paroxetine hydrochloride		✔				99%
Rocuronium Bromide		✔				98%
Tropicamide			+++ M4 mAChR, IC50: 8 nM			98%
Diphenmanil methylsulfate			✔			99%
Umeclidinium bromide			✔			95%
Otilonium bromide			✔			98%
Flavoxate HCl			+ mAChR, IC50: 12.2 μM			99%
Ipratropium bromide			✔			98%
Diphenidol HCl			✔			98%
Darifenacin hydrobromide			++++ M3 mAChR, pKi: 8.9			98%
Aclidinium Bromide			++++ M2 mAChR, Ki: 0.1 nM M4 mAChR, Ki: 0.21 nM			98%
Oxybutynin chloride			✔			99%
Pentoxyverine citrate			✔			98%
Solifenacin			✔			98%
Catharanthine				✔		98%
Benzethonium chloride				+++ α4β2 nAChRs, IC50: 49 nM α7 nAChRs, IC50: 122 nM		99+%
Vinblastine sulfate				+ nAChR, IC50: 8.9 μM		99%
PNU-120596				++ α7 nAChR, EC50: 216 nM		99+%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Dronedarone 生物活性

描述

Dronedarone is an amiodarone-like benzofuran which lacks the iodine moiety and presents a methane sulfonyl group that decreases its lipophilicity, thus shortening the half-life and decreasing tissue accumulation. Dronedarone blocks multiple cardiac ion channels and β-adrenoceptors, presenting electrophysiological characteristics of all four Vaughan-Williams classes of antiarrhythmic drugs. Dronedarone was more effective than placebo in maintaining sinus rhythm in patients with paroxysmal and/or persistent AF and was also effective for ventricular rate control during AF (Atrial fibrillation) recurrences, providing incremental rate control on top of standard drugs in permanent AF^[3]. Dronedarone decreases the incidence of AF recurrence and the ventricular rate during recurrence. Dronedarone increases mortality in patients with permanent AF and those with moderate-severe heart failure, and should thus be avoided in these populations. Dronedarone is less effective than amiodarone but also has less toxicity^[4]. Furthermore, the beneficial effects of oral dronedarone on ventricular rate control were maintained during exercise and sustained with continued therapy. Oral dronedarone was generally well tolerated in the treatment of adult patients with AF and/or atrial flutter in clinical studies^[5].

Dronedarone 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01288352	Atrial Fibrillation ... 展开 >> Stroke 收起 <<	Phase 4	Active, not recruiting	November 2019	Belgium ... 展开 >> 14 Sites Different, Belgium Czech Republic 4 Sites Different, Czech Republic Denmark 2 Sites Different, Denmark France 2 Sites Different, France Germany 51 Sites Different, Germany Italy 12 Sites Different, Italy Netherlands 13 Sites Different, Netherlands Poland 5 Sites Different, Poland Spain 10 Sites Different, Spain Switzerland 5 Sites Different, Switzerland United Kingdom 22 Sites Different, United Kingdom 收起 <<
NCT03607123	-		Active, not recruiting	July 4, 2022	China, Jiangsu ... 展开 >> The First Affiliated Hospital of Nanjing Medical University Nanjing, Jiangsu, China, 201129 收起 <<
NCT00911508	Atrial Fibrillation ... 展开 >> Arrhythmia 收起 <<	Not Applicable	Completed	-	-

Dronedarone 参考文献

[1]Piccinni C, Raschi E, et al. Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden. Eur J Clin Pharmacol. 2013 Mar;69(3):715-20.

[2]Benaim G, Paniz Mondolfi AE. The emerging role of amiodarone and dronedarone in Chagas disease. Nat Rev Cardiol. 2012 Oct;9(10):605-9.

[3]Tamargo J, López-Farré A, Caballero R, Delpón E. Dronedarone. Drugs Today (Barc). 2011;47(2):109-133

[4]Tadros R, Nattel S, Andrade JG. Dronedarone: Basic Pharmacology and Clinical Use. Card Electrophysiol Clin. 2016;8(2):453-465

[5]Hoy SM, Keam SJ. Dronedarone. Drugs. 2009;69(12):1647-1663

Dronedarone 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

1.80mL

0.36mL

0.18mL

8.98mL

1.80mL

0.90mL

17.96mL

3.59mL

1.80mL

Dronedarone 技术信息

CAS号	141626-36-0
分子式	C₃₁H₄₄N₂O₅S
分子量	556.756

别名	SR 33589
运输	蓝冰

存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Sealed in dry,2-8°C

溶解方案

细胞实验：

DMSO: 50 mg/mL(89.81 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01288352	Atrial Fibrillation ... 展开 >> Stroke 收起 <<	Phase 4	Active, not recruiting	November 2019	Belgium ... 展开 >> 14 Sites Different, Belgium Czech Republic 4 Sites Different, Czech Republic Denmark 2 Sites Different, Denmark France 2 Sites Different, France Germany 51 Sites Different, Germany Italy 12 Sites Different, Italy Netherlands 13 Sites Different, Netherlands Poland 5 Sites Different, Poland Spain 10 Sites Different, Spain Switzerland 5 Sites Different, Switzerland United Kingdom 22 Sites Different, United Kingdom 收起 <<
NCT03607123	-		Active, not recruiting	July 4, 2022	China, Jiangsu ... 展开 >> The First Affiliated Hospital of Nanjing Medical University Nanjing, Jiangsu, China, 201129 收起 <<
NCT00911508	Atrial Fibrillation ... 展开 >> Arrhythmia 收起 <<	Not Applicable	Completed	-	-
NCT02618577	Atrial High Rate Episodes	Phase 3	Recruiting	March 31, 2022	Austria ... 展开 >> Several Sites Recruiting Multiple Locations, Austria Belgium Several Sites Not yet recruiting Multiple Locations, Belgium Bulgaria Several Recruiting Multiple Locations, Bulgaria Czechia Several Recruiting Multiple Locations, Czechia France Several Recruiting Multiple Locations, France Germany Several Sites Recruiting Multiple Locations, Germany Hungary Several Recruiting Multiple Locations, Hungary Italy Several Recruiting Multiple Locations, Italy Netherlands Several Recruiting Multiple Locations, Netherlands Poland Several Recruiting Multiple Locations, Poland Portugal Several Recruiting Multiple Locations, Portugal Spain Several Recruiting Multiple Locations, Spain Sweden Several Recruiting Multiple Locations, Sweden Ukraine Several Recruiting Multiple Locations, Ukraine United Kingdom Several Recruiting Multiple Locations, United Kingdom 收起 <<
NCT03489395	Atrial Fibrillation	Phase 2	Recruiting	June 30, 2019	Italy ... 展开 >> Ospedale Madonna del Soccorso Active, not recruiting San Benedetto Del Tronto, Ascoli Piceno, Italy, 63074 Presidio Ospedaliero S. Maria delle Grazie Active, not recruiting Pozzuoli, Napoli, Italy, 80078 AORN S.ANNA e S.SEBASTIANO Not yet recruiting Caserta, Italy, 81100 Contact: Paolo Calabrò 00393284346963 paolo.calabro@unicampania.it Università degli Studi G. D'Annunzio Active, not recruiting Chieti, Italy, 66013 Ospedale P. Monaldi Not yet recruiting Napoli, Italy, 80131 Contact: Antonio D'Onofrio 0039337768956 donofrioant1@gmail.com Policlinico AO di Padova Not yet recruiting Padova, Italy, 35128 Contact: Vittorio Pengo 00393298324844 vittorio.pengo@unipd.it Policlinico Universitario Campus Bio-Medico Recruiting Roma, Italy, 00128 Contact: Giuseppe Patti 00393394296745 g.patti@unicampus.it 收起 <<
NCT02825979	Atrial Fibrillation	Not Applicable	Recruiting	June 2022	Canada, Alberta ... 展开 >> Libin CV Calgary Recruiting Calgary, Alberta, Canada Contact: Jacques Rizkallah, MD Royal Alexandra Recruiting Edmonton, Alberta, Canada Contact: Evan Lockwood, MD Canada, British Columbia St. Paul's Hospital Recruiting Vancouver, British Columbia, Canada Contact: Dr. Zachary Laksman, MD Vancouver General Hospital Recruiting Vancouver, British Columbia, Canada Contact: Jason Andrade, MD Principal Investigator: Jason Andrade, MD Victoria Cardiac Arrhythmia Trials Recruiting Victoria, British Columbia, Canada, V8T 1Z4 Contact: Paul Novak, M.D. Canada, Nova Scotia Queen Elizabeth II Recruiting Halifax, Nova Scotia, Canada Contact: Dr. John Sapp, MD Canada, Ontario Hamilton Health Sciences Recruiting Hamilton, Ontario, Canada, L8L 2X2 Contact: Guy Amit, M.D. St. Mary's Kitchener Recruiting Kitchener, Ontario, Canada, N2M 1B2 Contact: Umjeet Jolly, M.D. London Health Sciences Centre Recruiting London, Ontario, Canada Contact: Peter Leong-Sit, MD Southlake Regional Health Centre Recruiting Newmarket, Ontario, Canada Contact: Dr. Atul Verma, MD University of Ottawa Heart Institute Not yet recruiting Ottawa, Ontario, Canada, K1Y4W7 Principal Investigator: Girish Nair, MD Rouge Valley Health System Recruiting Scarborough, Ontario, Canada Contact: Derek Yung, MD St. Michael's Hospital Recruiting Toronto, Ontario, Canada Contact: Paul Angaran, MD Canada, Quebec McGill University Health Centre Recruiting Montreal, Quebec, Canada Contact: Vidal Essebag, MD Hôpital du Sacré-Cœur de Montréal Recruiting Montréal, Quebec, Canada, H4J 1C5 Contact: Marcio Sturmer, M.D. Institut Universitaire de Cardiologie et de Pneumologie de Quebec Recruiting Quebec city, Quebec, Canada Contact: Jean Champagne, MD Le Centre hospitalier universitaire de Sherbrooke CHUS Recruiting Sherbrooke, Quebec, Canada Contact: Jean-Francois Roux, MD Canada, Saskatchewan University of Saskatchewan Recruiting Saskatoon, Saskatchewan, Canada Contact: Dr. Stephan Wardell, MD 收起 <<
NCT01411371	Atrial Fibrillation ... 展开 >> Heart Failure 收起 <<	Not Applicable	Unknown	October 2011	United Kingdom ... 展开 >> Barts & The London NHS Trust Recruiting London, UK, United Kingdom, EC1A 7BE Contact: Ross J Hunter, MRCP 442076018639 ross.hunter@bartsandthelondon.nhs.uk Principal Investigator: Richard J Schilling, MD FRCP Sub-Investigator: Ross J Hunter, MRCP 收起 <<
NCT02294955	Atrial Fibrillation ... 展开 >> Quality of Life 收起 <<	Not Applicable	Active, not recruiting	September 2018	Sweden ... 展开 >> Carina Blomström Lundqvist Uppsala, Sweden, S-75185 收起 <<
NCT01306162	Healthy	Phase 1	Completed	-	Germany ... 展开 >> 1160.112.1 Boehringer Ingelheim Investigational Site Ulm, Germany 收起 <<
NCT01856075	-		Completed	-	Germany ... 展开 >> Praxis fuer Kardiologie, Im Muehlenbach 2B Bonn, Germany, 53127 收起 <<
NCT01182376	Atrial Fibrillation	Phase 3	Completed	-	-
NCT00697086	Atrial Fibrillation	Phase 3	Completed	-	Belgium ... 展开 >> Sanofi-aventis Administrative Office Diegem, Belgium Czech Republic Sanofi-aventis Administrative Office Praha, Czech Republic France Sanofi-aventis Administrative Office Paris, France Italy Sanofi-aventis Administrative Office Milano, Italy Netherlands Sanofi-aventis Administrative Office Gouda, Netherlands Poland Sanofi-aventis Administrative Office Warszawa, Poland Spain Sanofi-aventis Administrative Office Barcelona, Spain Sweden Sanofi-aventis Administrative Office Bromma, Sweden Switzerland Sanofi-aventis Administrative Office Geneva, Switzerland 收起 <<
NCT01182376	-		Completed	-	-
NCT01140581	Atrial Fibrillation	Phase 4	Completed	-	-
NCT01213368	Atrial Fibrillation	Phase 2	Completed	-	Japan ... 展开 >> Investigational Site Number 392022 Hiroshima-Shi, Japan Investigational Site Number 392018 Kagoshima-Shi, Japan Investigational Site Number 392005 Kasama-Shi, Japan Investigational Site Number 392014 Kawanishi-Shi, Japan Investigational Site Number 392008 Kawasaki-Shi, Japan Investigational Site Number 392007 Kisarazu-Shi, Japan Investigational Site Number 392012 Kobe-Shi, Japan Investigational Site Number 392013 Kobe-Shi, Japan Investigational Site Number 392003 Koriyama-Shi, Japan Investigational Site Number 392017 Kurume-Shi, Japan Investigational Site Number 392023 Miyazaki-Shi, Japan Investigational Site Number 392009 Nagano-Shi, Japan Investigational Site Number 392019 Nagasaki-Shi, Japan Investigational Site Number 392010 Osaka-Shi, Japan Investigational Site Number 392021 Sapporo-Shi, Japan Investigational Site Number 392025 Sapporo-Shi, Japan Investigational Site Number 392002 Sendai-Shi, Japan Investigational Site Number 392004 Shirakawa-Shi, Japan Investigational Site Number 392016 Shunan-Shi, Japan Investigational Site Number 392020 Suwa-Shi, Japan Investigational Site Number 392006 Takasaki-Shi, Japan Investigational Site Number 392001 Tomakomai-Shi, Japan Investigational Site Number 392024 Toshima-Ku, Japan Investigational Site Number 392015 Ube-Shi, Japan Investigational Site Number 392011 Yao-Shi, Japan 收起 <<
NCT01522651	Atrial Fibrillation	Phase 2	Completed	-	-
NCT00174785	-		Completed	-	-
NCT01306162	-		Completed	-	-
NCT00259376	Atrial Fibrillation ... 展开 >> Atrial Flutter 收起 <<	Phase 3	Completed	-	United States, New Jersey ... 展开 >> Sanofi-Aventis Administrative Office Bridgewater, New Jersey, United States, 08807 Argentina Sanofi-Aventis Administrative Office Buenos Aires, Argentina Australia sanofi-aventis Australia administrative office Macquarie Park, Australia Canada Sanofi-Aventis Administrative Office Laval, Canada South Africa Sanofi-Aventis Administrative Office Midrand, South Africa 收起 <<
NCT01047566	Atrial Fibrillation	Phase 4	Completed	-	Netherlands ... 展开 >> Sanofi-Aventis Administrative Office PE Gouda, Netherlands 收起 <<
NCT00174785	Atrial Fibrillation ... 展开 >> Atrial Flutter 收起 <<	Phase 3	Completed	-	-
NCT01430806	ICD ICD SHOCK... 展开 >>S DRONEDARONE 收起 <<	Not Applicable	Unknown	December 2015	-
NCT00259428	Atrial Fibrillation ... 展开 >> Atrial Flutter 收起 <<	Phase 3	Completed	-	Belgium ... 展开 >> Sanofi-Aventis Administrative Office Diegem, Belgium Czech Republic Sanofi-Aventis Administrative Office Praha, Czech Republic Denmark Sanofi-Aventis Administrative Office Horsholm, Denmark Finland Sanofi-Aventis Administrative Office Helsinki, Finland France Sanofi-Aventis Administrative Office Paris, France Germany Sanofi-Aventis Administrative Office Berlin, Germany Hungary Sanofi- Aventis Administrative Office Budapest, Hungary Italy Sanofi-Aventis Administrative Office Milano, Italy Netherlands Sanofi-Aventis Administrative Office Gouda, Netherlands Poland Sanofi-Aventis Administrative Office Warszawa, Poland Spain Sanofi-Aventis Administrative Office Barcelona, Spain United Kingdom Sanofi-Aventis Administrative Office Guildford, United Kingdom 收起 <<
NCT00696631	Congestive Heart Failure	Phase 3	Terminated(Terminated as the a... 展开 >>ctive treatment was associated with an increased hazard) 收起 <<	-	Denmark ... 展开 >> Sanofi-aventis Administrative Office Horsholm, Denmark Hungary Sanofi-aventis Administrative Office Budapest, Hungary Netherlands Sanofi-aventis Administrative Office Gouda, Netherlands Norway Sanofi-aventis Administrative Office Lysaker, Norway Poland Sanofi-aventis Administrative Office Warszawa, Poland Sweden Sanofi-aventis Administrative Office Bromma, Sweden 收起 <<
NCT01266681	Atrial Fibrillation	Not Applicable	Unknown	-	United Kingdom ... 展开 >> Eastbourne General Hospital Not yet recruiting Eastbourne, East Sussex, United Kingdom, BN21 2UD Sub-Investigator: Oliver Waller, Bsc (hons) 收起 <<
NCT01991119	Atrial Fibrillation	Not Applicable	Completed	-	Korea, Republic of ... 展开 >> Cardiac and Vascular Center Seoul, Korea, Republic of, 135-710 收起 <<
NCT00489736	-		Completed	-	-
NCT00489736	Atrial Fibrillation	Phase 3	Completed	-	-
NCT01026090	Atrial Fibrillation	Phase 4	Terminated('Sponsor decision f... 展开 >>ollowing recruitment issues, not related to any safety concerns in the study) 收起 <<	-	Canada ... 展开 >> Investigational Site Number 1240033 Abbotsford, Canada, V2S3N5 Investigational Site Number 1240026 Barrie, Canada, L4M4S5 Investigational Site Number 1240050 Calgary, Canada, T2E7C5 Investigational Site Number 1240010 Cambridge, Canada, N1R6V6 Investigational Site Number 1240049 Edmonton, Canada, T5H4B9 Investigational Site Number 1240005 Granby, Canada, J2G1T7 Investigational Site Number 1240001 Greenfield Park, Canada, J4V2G8 Investigational Site Number 1240046 Grimsby, Canada, L3M 1P3 Investigational Site Number 1240040 Hamilton, Canada, L8L 2X2 Investigational Site Number 1240037 Hamilton, Canada, L8N 3Z5 Investigational Site Number 1240044 Kingston, Canada, K7L2V7 Investigational Site Number 1240029 Kitchener, Canada, N2N2A8 Investigational Site Number 1240013 Laval, Canada, H7S2M5 Investigational Site Number 1240043 Levis, Canada, G6V3Z1 Investigational Site Number 1240038 Maple Ridge, Canada, V2X5Z6 Investigational Site Number 1240023 Montreal, Canada, H1T1C8 Investigational Site Number 1240006 Montreal, Canada, H3G 1A4 Investigational Site Number 1240008 Montreal, Canada, H4J1C5 Investigational Site Number 1240018 Newmarket, Canada, L3Y8C3 Investigational Site Number 1240012 Niagara Falls, Canada, L2E7H1 Investigational Site Number 1240020 North York, Canada, M2J1W8 Investigational Site Number 1240015 Oshawa, Canada, L1J2J9 Investigational Site Number 1240036 Oshawa, Canada Investigational Site Number 1240024 Ottawa, Canada, K1Y4W7 Investigational Site Number 1240032 Ottawa, Canada, K2G3M8 Investigational Site Number 1240056 Red Deer, Canada, T4N4E7 Investigational Site Number 1240053 Saskatoon, Canada, S7N0W8 Investigational Site Number 1240016 Scarborough, Canada, M1E5E9 Investigational Site Number 1240027 Sherbrooke, Canada, J1H 5N4 Investigational Site Number 1240003 St-Charles Borromee, Canada, J6E6J2 Investigational Site Number 1240007 St-Georges, Canada, G5Y 4T8 Investigational Site Number 1240041 St. John, Canada, E2L 4L2 Investigational Site Number 1240002 Ste-Foy, Canada, G1V4G5 Investigational Site Number 1240021 Sudbury, Canada, P3C5K7 Investigational Site Number 1240039 Sudbury, Canada, P3E2N8 Investigational Site Number 1240025 Toronto, Canada, M4N3M5 Investigational Site Number 1240011 Toronto, Canada, M5C 2T2 Investigational Site Number 1240019 Toronto, Canada, M5G2C4 Investigational Site Number 1240009 Trois-Rivières, Canada, G8Z 4K4 Investigational Site Number 1240047 Vancouver, Canada, V5Z1M6 Investigational Site Number 1240035 Victoria, Canada, V8R4R2 Investigational Site Number 1240014 Willowdale, Canada, M2K2W2 Investigational Site Number 1240051 Windsor, Canada, N8X3N9 收起 <<
NCT01151137	Atrial Fibrillation	Phase 3	Terminated(The study was stopp... 展开 >>ed because of safety concerns) 收起 <<	-	-
NCT01151137	-		Terminated(The study was stopp... 展开 >>ed because of safety concerns) 收起 <<	-	-
NCT01198873	Atrial Fibrillation	Phase 4	Terminated	-	-
NCT01135017	Atrial Fibrillation	Phase 4	Terminated	-	-
NCT01135017	-		Terminated	-	-
NCT01198873	-		Terminated	-	-
NCT01070667	Paroxysmal Atrial Fibrillation	Phase 4	Unknown	March 2010	United Kingdom ... 展开 >> Eastbourne DGH Not yet recruiting Eastbourne, East Sussex, United Kingdom, BN21 2UD Contact: Steven J Podd, MA, MBBS 01323417400 ext 4132 steven.podd@esht.nhs.uk Contact: A N Sulke, MD 01323417400 ext 5869 pamela.morley@esht.nhs.uk 收起 <<
NCT01199081	Atrial Fibrillation	Phase 4	Completed	-	-

决奈达隆 /Dronedarone {[allProObj[0].p_purity_real_show]}

Dronedarone 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Dronedarone 质控信息

Dronedarone 生物活性

Dronedarone 临床研究

Dronedarone 参考文献

Dronedarone 实验方案

Dronedarone 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

决奈达隆 /Dronedarone {[allProObj[0].p_purity_real_show]}

Dronedarone 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Dronedarone 质控信息

Dronedarone 生物活性

Dronedarone 临床研究

Dronedarone 参考文献

Dronedarone 实验方案

Dronedarone 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Dronedarone 纯度/质量文件产品仅供科研